VECTURA GROUP (LSE:VEC)

 

VECTURA GROUP (VEC.L, LSE, LSE:VEC)

VEC Share PerformanceMore

52 week high171.50 19/02/14
52 week low113.25 16/10/14
52 week change -3.25 (-2.09%)
4 week volume7,170,005 30/12/14

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Director Deals - Vectura Group PLC (VEC)

Dr Trevor Phillips, Executive Director, exercised 208,877 shares in the company on the 15th January 2015 at a price of 95.75...

Director Deals - Vectura Group PLC (VEC)

Dr Trevor Phillips, Executive Director, exercised 208,877 shares in the company on the 15th January 2015 at a price of 95.75...

Director Deals - Vectura Group PLC (VEC)

Dr Trevor Phillips, Executive Director, exercised 208,877 shares in the company on the 15th January 2015 at a price of 95.75...

Director/PDMR Shareholding

RNS Number: 3754C Vectura Group plc 16 January 2015 Notification of Transactions of Directors/Persons Discharging Managerial Responsibility and Connected Persons All relevant boxes should be completed in block capital letters. 1. Name of the issuer 2. State whether the notification relates to (i) a transaction notified in accordance with DTR 3.1.2 R, (ii) a disclosure...

Vectura to present at JP Morgan Conference

RNS Number: 5910B Vectura Group plc 09 January 2015 Vectura Group plc Vectura to present at the 33rd Annual J.P. Morgan Healthcare Conference, San Francisco Chippenham, UK - 9 January 2015: Vectura Group plc ("Vectura"; LSE: VEC) announces today that it is scheduled to present at the 33rd Annual J.P. Morgan Healthcare Conference on Wednesday, 14 Jan...

VEC says robust Phase III results for QCA149, NVA237

Vectura Group confirms the information released today by partner Novartis announcing the New Drug Applications (ND...

US submission for NVA237 and QVA149

RNS Number: 5943B Vectura Group plc 08 January 2015 Vectura Group plc Submission of regulatory applications to US FDA and robust Phase III results for QVA149 and NVA237 Submissions to US FDA completed for QVA149 and NVA237 in Q4 2014 Pivotal Phase III results for QVA149 and NVA237 met their primary endpoints and significantly improved lung f...

Vectura says development and licence agreement with Janssen

Vectura Group has entered into a global development and licence agreement with Janssen Biotech for the exclusive develo...

Fundamental DataMore

EPS-0.7
Dividend yield0 %

Users' HoldingsMore

Users who hold VECTURA GROUP also hold..
LLOYDS BANKING GRP19%
VODAFONE GROUP16%
BP15%
GLAXOSMITHKLINE13%
BARCLAYS13%